Hyderabad: Genome Valley-based ATGC Biotech, pioneers in pheromone and semiochemical-based crop protection, announced on Monday, December 8, the launch of Semiophore Ltd. — a 50:50 Indo-Israeli joint venture with Luxembourg Industries Ltd.
This strategic partnership positions Hyderabad as a global hub for innovative, sustainable agriculture solutions, blending ATGC’s cutting-edge IP, technology, and R&D expertise with Israeli industrial prowess.
Genome Valley’s Historic Indo-Israeli Biotech JV: First-Ever Tech Out-Licensing to Israel
The joint venture with Israel’s Luxembourg Industries marks a milestone — the first out-licensing of Indian semiochemical technology to Israel. Semiophore Ltd. will scale up 18 advanced semiochemical and pheromone technologies, tapping into a multi-billion-dollar global market opportunity.
Semiophore and its JV partner plan to invest $10 million in registrations, marketing, and facility upgrades. At full maturity, each product is projected to generate USD 75–100 million through widespread adoption in horticulture and broad-acre row crops.
The licensing agreements exchange took place at the Valedictory Session of the First International Science & Technology (S&T) Clusters Conference in New Delhi. Under the JV terms, ATGC Biotech provides IP, technology, know-how, regulatory dossiers, capex, and R&D leadership, while Luxembourg Industries covers capex, regulatory, marketing, and manufacturing costs.
ATGC Biotech hailed the event as “a defining moment for India’s bioeconomy and the global semiochemical industry.” For the first time, Indian-developed semiochemical technologies will be manufactured and commercialized in Israel, ushering in a new era of Indo-Israeli scientific and industrial collaboration.
